Advertisement
Screener

Monopar Therapeutics Inc. (MNPR) Graph

MNPR Revenue Flow

Filed revenue amounts for 2026-01-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue (m); Research and development $4.77M; Operating expenses $6.64M; Net income -$5.31M.
  • 2026-03-31: Revenue $0.00; Research and development $3.49M; Operating expenses $5.23M; Net income -$3.89M.
  • 2025-12-31: Revenue (m); Research and development $3.94M*; Operating expenses $6.16M*; Net income -$5.20M*.
  • 2025-09-30: Revenue (m); Research and development $2.59M; Operating expenses $4.09M; Net income -$3.44M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

MNPR revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$0.00Operating expenses$11.87MOperating income-$11.87MResearch & development$8.25M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30(m)$4.77M$6.64M-$5.31M
2026-03-31$0.00$3.49M$5.23M-$3.89M
2025-12-31(m)$3.94M*$6.16M*-$5.20M*
2025-09-30(m)$2.59M$4.09M-$3.44M
2025-06-30(m)$1.73M$3.23M-$2.45M
2025-03-31(m)$1.64M$3.22M-$2.62M
2024-09-30(m)$984.28K$1.57M-$1.30M
2024-06-30(m)$1.13M$1.79M-$1.72M
2024-03-31(m)$966.11K$1.72M-$1.64M
2023-09-30(m)$1.32M$2.07M-$1.95M
2023-06-30(m)$1.59M$2.33M-$2.20M
2023-03-31(m)$1.65M$2.53M-$2.43M
2022-09-30(m)$1.73M$2.41M-$2.40M
2022-06-30(m)$2.08M$2.76M-$2.76M
2022-03-31(m)$1.68M$2.46M-$2.46M
2021-09-30(m)$1.83M$2.46M-$2.46M
2021-06-30(m)$1.48M$2.09M-$2.08M
2021-03-31(m)$1.21M$1.89M-$1.88M
2020-09-30(m)$1.26M$1.65M-$1.64M
2020-06-30(m)$832.50K$1.46M-$1.45M
2020-03-31(m)$344.41K$1.14M-$1.09M
2019-12-31$0.00*(m)(m)(m)
2019-09-30$0.00$219.85K$759.45K-$736.08K
2019-06-30$0.00$329.29K$932.11K-$905.70K
2019-03-31$0.00$835.60K$1.41M-$1.38M
2018-12-31(m)(m)(m)-$890.46K
2018-09-30$0.00$303.68K$667.53K-$640.18K
2018-06-30$0.00$303.68K$667.53K-$640.18K
2018-03-31$0.00$457.14K$897.26K-$876.35K
2017-09-30$0.00$180.68K$14.90M-$14.88M
2017-06-30$0.00$311.59K$594.96K-$591.44K
2017-03-31$0.00$133.74K$373.84K-$372.92K

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30$0.00$8.25M$11.87M-$9.21M
2025-06-30(m)$3.37M$6.46M-$5.08M
2024-06-30(m)$2.10M$3.51M-$3.36M
2023-06-30(m)$3.25M$4.85M-$4.63M
2022-06-30(m)$3.76M$5.22M-$5.22M
2021-06-30(m)$2.68M$3.99M-$3.96M
2020-06-30(m)$1.18M$2.60M-$2.54M
2019-06-30$0.00$1.16M$2.34M-$2.28M
2018-06-30$0.00$949.79K$1.74M-$1.70M
2017-06-30$0.00$445.33K$968.80K-$964.36K

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-09-30(m)$5.96M$10.55M-$8.52M
2024-09-30(m)$3.08M$5.09M-$4.66M
2023-09-30(m)$4.56M$6.92M-$6.59M
2022-09-30(m)$5.49M$7.63M-$7.62M
2021-09-30(m)$4.51M$6.45M-$6.42M
2020-09-30(m)$2.43M$4.25M-$4.18M
2019-09-30$0.00$1.38M$3.10M-$3.02M
2018-09-30$0.00$1.25M$2.40M-$2.34M
2017-09-30$0.00$626.00K$15.87M-$15.84M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$0.00$9.90M$16.70M$800.00-$13.72M
2024-12-31$0.00$13.01M$16.16M$800.00-$15.59M
2023-12-31(m)$5.60M$8.83M$800.00-$8.40M
2022-12-31(m)$7.59M$10.54M$800.00-$10.52M
2021-12-31(m)$6.49M$9.13M$0.00-$9.10M
2020-12-31(m)$4.07M$6.51M$18.36K-$6.30M
2019-12-31$0.00$1.97M$4.32M$0.00-$4.22M
2018-12-31$0.00$1.77M$3.33M-$70.81K-$3.23M
2017-12-31$0.00$935.32K$16.60M-$3.56K-$16.55M
2016-12-31$0.00$280.36K$1.19M$800.00-$1.19M

Similar stocks

Stock NameCountryMarket CapPE Ratio
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Altimmune, Inc. (ALT)United States$0.593B-6.43
CorMedix Inc. (CRMD)United States$0.605B3.25
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
Neurogene Inc. (NGNE)$0.625B-4.46
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Indaptus Therapeutics, Inc. (INDP)United States$0.537B